Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: The SUPER GATE study için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: The SUPER GATE study | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Ekim 2024 | 0 |
| Kasım 2024 | 0 |
| Aralık 2024 | 0 |
| Ocak 2025 | 0 |
| Şubat 2025 | 0 |
| Mart 2025 | 0 |
| Nisan 2025 | 0 |
Dosya Ziyaretleri
| views | |
|---|---|
| satilmis-bilgin.pdf | 1 |
